Insulin-like growth factor 1 (IGF1) has been proposed as a ''G 1 -progression factor'' and as a mediator of estradiol's (E2) mitogenic effects on the uterus. To test these hypotheses, we compared E2's mitogenic effects on the uteri of Igf1-targeted gene deletion (null) and wild-type littermate mice. The proportion of uterine cells involved in the cell cycle and G 1 -and S-phase kinetics were not significantly different in wild-type and Igf1-null mice. However, the appearance of E2-induced mitotic figures and cell number increases were profoundly retarded in Igf1-null uterine tissue. There was a significant increase in nuclear DNA concentration in Igf1-null cells, consistent with a G 2 arrest. Interestingly, apoptotic cells were also significantly reduced in abundance, and the normal massive apoptotic response to E2 withdrawal was absent in the Igf1-null uterus. These data show that Igf1 is an essential mediator of E2's mitogenic effects, with a critical role not in G 1 progression but in G 2 progression.
Estradiol (E2) has potent stimulatory effects on uterine growth, with unopposed E2 action culminating in uterine neoplasia. Media from E2-treated uterine explants contains factors capable of stimulating tumor cell proliferation, suggesting that E2's mitogenic effects are mediated by local growth factor production (1). Insulin-like growth factor 1 (IGF1) has been implicated as a potential mediator of E2's effects on uterine growth [''estromedin'' (2)] because E2 induces uterine IGF1 expression (3) (4) (5) (6) (7) (8) (9) (10) (11) in a pattern that shows a significant spatiotemporal correlation with E2-induced cell proliferation (11) . Furthermore, Igf1-targeted gene deletion mice demonstrate a disproportionate reduction in uterine size, although it is not clear whether this is caused by reduced estrogen production (12) or by impaired estrogen effect on the uterus secondary to absent local IGF1. To test the hypothesis that IGF1is required for E2-induced mitogenesis and to identify the cell-cycle stages in which IGF1 acts in vivo, we compared the effects of exogenous E2 treatment on uterine cell-cycle parameters in homozygous Igf1 null and wild-type (wt) littermate mice.
METHODS AND RESULTS
The mice used in this study were from an Igf1 deletion line derived and genotyped as previously described (13) . Postnatal day 40 (P40) Igf1 null and wt littermate female mice were treated with E2 or vehicle and killed 21 h later, 1 h after [ Table 1 ). Given the conventional view of IGF1 as a ''G 1 -progression factor'' (14) , finding equal proportions of cells in S phase in Igf1-null and wt uteri was unexpected. We considered the possibility that Igf1-null cells might have a prolonged S phase, increasing the probability of detecting cells in S phase and potentially obscuring a smaller proliferative fraction. However, cumulative labeling experiments (15) employing [ 3 H]thymidine and BrdUrd administered in series showed that S-phase influx, duration, and efflux were not significantly different in Igf1-null and wt mice ( Fig. 2 ; Table 2 ). Because previous work has shown that E2 has maximal effects on uterine-cell proliferation in prepubertal mice (16) , the experiments were repeated in P20 mice. E2-evoked DNA synthesis was equally robust in Igf1-null and wt uteri, except for a slightly reduced effect in Igf1-null myometrial cells (Fig. 3A) .
These data show that G 1 progression is normal despite IGF1 deletion. Furthermore, the double-labeling data show that Igf1-null cells transit S phase normally. There is, however, a problem between S and M phase, because mitotic figures are profoundly reduced in Igf1-null uteri (Fig. 3B) . The mitotic index was 3-4-fold higher in wt epithelium and approximately 7-fold higher in wt stroma and myometrium 21 h post-E2 treatment. Normally, the mitotic response peaks 20-24 h after a dose of E2 and returns to baseline by 48 h (17), at which time extensive apoptosis occurs in response to E2 withdrawal (18) . This was the pattern observed in wt mice. In Igf1-null mice, however, the MI was only modestly increased at 21 h, but remained significantly elevated 48 h post-E2 ( Fig. 4 ; Table 3 ), suggesting that some cells were still progressing from G 2 to M phase long after the E2 stimulus. One possible explanation for the discrepancy between the robust S-phase response and the dearth of mitotic figures is that large numbers of Igf1-null cells undergo programmed cell death after S phase. Intense scrutiny of uterine tissue by using in situ end labeling for detection of fragmented DNA as well as 4Ј,6-diamidino-2-phenylindole (DAPI) and hematoxylin staining for apoptotic bodies demonstrated that apoptosis was consistently more frequent in wt than in Igf1-null mice. Therefore, increased cell death is not responsible for the arrested cell cycle in the Igf1-null murine uterus. Interestingly, the massive apoptosis normally seen 48 h after E2 treatment failed to appear in the Igf1-null uterus ( Fig.  4 ; Table 3 ), suggesting, as a matter of speculation, that this response to E2 withdrawal depends on completion of the E2-induced mitotic cycle.
An alternative explanation for the discrepancy between S and M phase is that cells are arrested or retarded in the G 2 phase of the cell cycle in Igf1-null mice. This would explain the prolonged mitotic response, which is apparent 2 days after the The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. §1734 solely to indicate this fact.
PNAS is available online at www.pnas.org. There were no significant differences in LI between wt and Igf1 Ϫ͞Ϫ uterine cell populations either at baseline (vehicle- (19) , which may be relevant to the present observations, because we have observed a consistent reduction in cell size in the Igf1-null mice. The first day after E2 treatment, wt epithelial cell length from apical to basement membrane had increased by almost 200%, whereas Igf1-null epithelial cells had increased only Ϸ50% at this time point (Table 3) . Of interest, wt epithelial height declined after the 21 h timepoint, whereas Igf1-null epithelium continued to grow at least through the 48-h time point (Table 3 ). These data show that retardation in mitoses is correlated with retardation of cellular somatic growth in the absence of IGF1, suggesting that a G 2 checkpoint based on cell size, similar to that seen in yeast, might operate in this complex mammalian system. Table 2 ). 3 These data are from P20 mice, at which age the greatest proliferative response to E2 occurs. Similar data (14.7 Ϯ 2.1 vs. 4.0 Ϯ 1.3, respectively) were obtained from the analysis of the mitotic index in P40 wt and Igf1-null uterine epithelium. The mitotic index in other uterine cell types at P40 was so low in both wt and Igf1-null uteri that it was not counted. The values shown are means Ϯ SEM for 8-12 mice per group. The cumulative labeling index (LIcum, all labeled nuclei͞total nuclei) is equally increased over the single labeling index (LI1, 3 H-labeled nuclei͞total nuclei) in E2-treated Igf1 Ϫ͞Ϫ and wt mice, showing that S-phase duration is equal in the two groups. A further estimate of S-phase duration, given by the percentage of double-labeled nuclei (simultaneously BrdUrd and 3 H-positive) also was equal in both groups (data not shown). S-phase influx, represented by the percentage of BrdUrd-only positive nuclei, and efflux, represented by 3 H-only positive nuclei, also are equal in the two groups. All data are given as mean Ϯ SEM (percentage of all nuclei for each cell type). There were 3-6 mice in each group, and no statistically significant differences were found for any comparison between the two genotypes. Abbreviations are as in 
FIG. 2. To compare S-phase duration and flux in wt and

CONCLUSIONS
Studies in growth-arrested fibroblast cell lines established the view that growth factors act primarily in the G 1 phase of the cell cycle (14, 20) . Peptides such as PDGF, FGF, and EGF, termed ''competence factors,'' stimulated quiescent cells to enter G 1 , whereas IGF1 spurred progression through G 1 to S phase and therefore was deemed a G 1 -progression factor (14, 20, 21) . The present study analyzed the effects of IGF1 deletion on cell cycle dynamics in vivo, and has shown that (22) . In addition to defining a major role for IGF1 in G 2 as opposed to G 1 progression, this study demonstrates that IGF1 is in fact an important mediator of E2's mitogenic effects in the uterus. Together with previous evidence that E2 induces uterine IGF1 expression (3) (4) (5) (6) (7) (8) (9) (10) (11) , the present data shows that E2 induces uterine growth in two phases, with early events through S phase independent of IGF1, whereas later events culminating in mitosis are dependent on E2-induced IGF1 synthesis and action.
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